TALPHERA, INC. — Director's Dealing 2019

Nov 4, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACELRX PHARMACEUTICALS INC (ACRX)
CIK: 0001427925
Period of Report: 2019-11-02

Reporting Person: Angotti Vincent J. (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-11-02	Stock Option (Right to Buy)	$2.225	A	96250	Acquired	2028-11-02	Common Stock (96250)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	267565	Direct

Footnotes

F1: Balance includes non-reportable acquisition of 4,681 shares of Common Stock through the Company's Employee Stock Purchase Plan.

F2: On April 7, 2018, the reporting person was granted a performance-based option to purchase 192,500 shares of common stock, subject to the Company's achievement of commercial approval by the U.S. Food and Drug Administration ("FDA") of its new drug application for "DSUVIA" on or before February 15, 2019. Once the performance criteria is achieved, the option vests in two equal installments with 50% of the option vesting upon the Company's achievement of the performance criteria and the remaining 50% of the option vesting on the one-year anniversary of the date of such achievement, in all cases subject to continuous service to the Company. The performance criteria for commercial approval by the FDA for DSUVIA was met on November 2, 2018, resulting in vesting of the option as to 96,250 shares on that date. On November 2, 2019, the remaining balance of the option vested.